Organization | University of Verona

University of Verona Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Verona Italy (1982)

Organization Overview

First Clinical Trial

1999

NCT00473213

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

AOUI Verona | AOUI Verona - University of Verona | Azienda Ospedaliera Universitaria Integrata di Verona | Azienda Ospedaliera Universitaria Integrata Verona | Azienda Ospedaliera Universitaria Integrata Verona Italy | AZ.OSP.UNIVERSITARIA INTEGRATA VERONA- BORGO ROMA 05091202 | Centre for Tropical Diseases, Negrar (Verona), Italy | centro ricerche cliniche | Centro Ricerche Cliniche di Verona | Centro Ricerche Cliniche Verona | Department of Neurosciences, Biomedicine and Movement Sciences - University of Verona | Division of Cardiology, University of Verona, Italy | Fondazione Cariverona, Italy | General and Upper GI Surgery, University of Verona | Marialuisa Gandolfi | Neuromotor and Cognitive Rehabilitation Center Department for Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy P.zza L.A. Scuro, 10 37134 Verona, Italia | Ospedale Civile Maggiore | Ospedale Civile Maggiore, Divisione Neurologica, Piazzale Stefani1 37134 Verona | Pediatric Diabetes and Metabolic Disorders Unit, Department of Life and Reproduction Sciences, University of Verona | Policlinico G.B. Rossi, Verona | Univerisity of Verona | Universita di Verona | Universita of Verona | UniversitÃ di Verona | University Hospital of Verona | University Hospital Verona, Italy | University of Verona | University of Verona, AOUI Verona | U.O.C. Fibrosi Cistica - Azienda Ospedaliera Universitaria Integrata di Verona

Active Ingredients

Drugs in Phase 4 Trials (23)

acitretin (soriatane) (1 trial)

allopurinol (zyloprim) (1 trial)

aripiprazole (abilify) (1 trial)

citalopram (celexa) (1 trial)

cobalamin (1 trial)

efalizumab (Raptiva) (1 trial)

escitalopram (lexapro) (1 trial)

etoricoxib (Gencox) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

fluoxetine (prozac) (1 trial)

fluvoxamine (luvox) (1 trial)

folic acid (5 trials)

ibuprofen (motrin) (1 trial)

lithium (lithonate) (1 trial)

methotrexate (1 trial)

montelukast (singulair) (3 trials)

palmitoylethanolamide (1 trial)

paroxetine (paxil) (1 trial)

pyroglutamic acid (1 trial)

rimabotulinumtoxinB (Myobloc) (2 trials)

secukinumab (cosentyx) (1 trial)

sertraline (zoloft) (1 trial)

vortioxetine (trintellix) (1 trial)

Drugs in Phase 3 Trials (25)

acetylsalicylic acid (aspirin) (1 trial)

AZD1061 (1 trial)

AZD8895 (1 trial)

bamlanivimab (1 trial)

casirivimab (1 trial)

cisplatin (platinol) (2 trials)

cyclophosphamide (cytoxan) (1 trial)

fluorouracil (efudex) (4 trials)

gemcitabine (gemzar) (2 trials)

imdevimab (1 trial)

immune globulin (human) (Gamastan) (1 trial)

ivermectin (stromectol) (1 trial)

ketamine (ketalar) (1 trial)

leucovorin (3 trials)

methylprednisolone (medrol) (1 trial)

nirmatrelvir (Paxlovid) (1 trial)

oxaliplatin (eloxatin) (3 trials)

peginterferon beta-1a (Plegridy) (1 trial)

prasugrel (effient) (1 trial)

prednisone (meticorten) (1 trial)

ritonavir (Norvir) (1 trial)

rituximab (rituxan) (1 trial)

sodium chloride (1 trial)

sotrovimab (Xevudy) (2 trials)

surfactant (1 trial)

Drugs in Phase 2 Trials (17)

autologous mesenchymal stem cells (1 trial)

decitabine (dacogen) (1 trial)

docetaxel (taxotere) (1 trial)

gefitinib (iressa) (1 trial)

gimeracil (1 trial)

incobotulinumtoxinA (Xeomin) (1 trial)

ipilimumab (yervoy) (1 trial)

irinotecan (Camptosar) (3 trials)

levoleucovorin (fusilev) (1 trial)

libramed (1 trial)

mannitol (Osmitrol) (1 trial)

nivolumab (opdivo) (1 trial)

oteracil (1 trial)

pemetrexed (alimta) (1 trial)

tegafur (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 1 Trials (2)

itf2984 (1 trial)

teicoplanin (1 trial)

Drugs in Other Trials (14)

acetazolamide (diamox) (1 trial)

alpha-lipoic acid (1 trial)

bifidobacterium longum (1 trial)

hydroxocobalamin (cyanokit) (1 trial)

inositol (1 trial)

lactobacillus fermentum (1 trial)

lactobacillus plantarum (1 trial)

lactobacillus rhamnosus (1 trial)

lactose (1 trial)

myoinositol (3 trials)

n5-methyltetrahydropteroylglutamate (1 trial)

oxygen (1 trial)

progesterone (progestasert) (1 trial)

tomato (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Asthma (Phase 4)

Asthma, Exercise-Induced (Phase 4)

Atherosclerosis (Phase 3)

Bronchiolitis (Phase 3)

Bronchiolitis, Viral (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cerebral Palsy (Phase 4)

Congenital Abnormalities (Phase 3)

Coronary Artery Disease (Phase 3)

Cystic Fibrosis (Phase 2)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Diabetes Mellitus (Phase 4)

Fibromyalgia (Phase 4)

Fibrosis (Phase 2)

Glomerulonephritis (Phase 3)

Glomerulonephritis, Membranous (Phase 3)

Heart Diseases (Phase 3)

Heart Failure (Phase 4)

Lung Neoplasms (Phase 2)

Metabolic Syndrome (Phase 4)

Multiple Sclerosis (Phase 3)

Myocardial Ischemia (Phase 3)

Myofascial Pain Syndromes (Phase 4)

Pancreatic Neoplasms (Phase 3)

Paralysis (Phase 4)

Pneumonia (Phase 3)

Postpoliomyelitis Syndrome (Phase 3)

Psoriasis (Phase 4)

Respiratory Sounds (Phase 4)

Schizophrenia (Phase 4)

Sclerosis (Phase 3)

Status Epilepticus (Phase 3)

Strongyloidiasis (Phase 3)

Syndrome (Phase 4)

Thrombosis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 50
# of Trial APIs: 81